- Poster presentation
- Open Access
Cancers in DNA mismatch repair mutation carriers: results from a hospital based Lynch syndrome registry
Hereditary Cancer in Clinical Practice volume 9, Article number: P31 (2011)
The spectrum of cancers seen in a hospital based Lynch syndrome registry was examined to compare the incidence of colorectal versus extracolonic cancers by sex, race, mismatch repair (MMR) gene mutation, age at diagnosis and index cancer. We also examined rare extracolonic cancers that are not considered to be part of Lynch syndrome.
There were a total of 463 cancers recorded in 239 patients from 150 families enrolled in the Lynch syndrome registry at MD Anderson Cancer Center. Each of these patients had a confirmed germline MMR mutation. Overall there were 218 (47.1%) colorectal and 245 (52.9%) extracolonic cancers. There was no difference in the total number of colorectal and extracolonic cancers in MLH1 mutation carriers (50.3% vs 49.7%) whereas for MSH2 and MLH6 mutation carriers there were more extracolonic than colorectal cancers overall (54.2% vs. 45.8% for MSH2 and 61.9% vs. 38.1% for MSH6). Men had fewer extracolonic cancers than colorectal (44.6% vs. 55.4%), whereas women had more extracolonic cancers than colorectal (58.9% vs. 41.1%). The mean age at diagnosis for extracolonic cancers was older than for colorectal, 48.6 vs. 44.5 years (P=<0.001). There were no significant differences by race between the colorectal and extracolonic cancers in Whites, African Americans and Hispanics.
The index cancer was colorectal in 54.8% of patients. Among the extracolonic index cancers endometrial/uterine was the most common (29.6%) followed by skin (24.1%, of which 11.1% were confirmed cases of Muir-Torre). Other index cancers were renal/ureter/bladder (10.2%), upper GI/small intestine (6.5%), ovary (5.6%) and hepatobiliary/pancreas (3.7%). It was interesting to note that the index tumor was breast cancer in 5 patients (4.6%) although breast cancer is not considered part of Lynch syndrome [1–3]. Other non-Lynch syndrome index cancers recorded were prostate (n=3, 2.8%), thyroid (n=2, 1.85%), cervix/vagina (n=2, 1.85%) and 1 case each of thymoma, leukemia, lymphoma soft palate, adenocarcinoma of the lung and fibroxanthoma peritoneum. In addition, there was 1 index brain tumor and 4 patients presented with metastatic disease (lung, liver, unknown primary).
In this study, we found that Lynch syndrome patients can commonly present with cancers other than colorectal and endometrial. This has clinical relevance both for diagnosis of Lynch syndrome and surveillance for cancers of different sites during followup of these patients.
Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la CA, et al.: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81: 214–218. 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L
Scott RJ, Ashton KA: Familial breast and bowel cancer: does it exist? Hered Cancer Clin Pract 2004, 2: 25–29. 10.1186/1897-4287-2-1-25
Vasen HF, Morreau H, Nortier JW: Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? Am J Hum Genet 2001, 68: 1533–1535. 10.1086/320610
About this article
Cite this article
Pande, M., Amos, C., Lynch, P. et al. Cancers in DNA mismatch repair mutation carriers: results from a hospital based Lynch syndrome registry. Hered Cancer Clin Pract 9, P31 (2011). https://doi.org/10.1186/1897-4287-9-S1-P31
- Breast Cancer
- Mutation Carrier
- Lynch Syndrome
- Mismatch Repair